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Introduction
Hypertension currently affects approximately one bil-
lion adults globally. It is a major risk factor for car-
diovascular diseases (CV) and stroke and is
associated with metabolic syndromes including insu-
lin resistance and lipid abnormalities. The high prev-
alence of hypertension has contributed to the present
pandemic of CV disease, which now accounts for
30% of all deaths worldwide (1). As the population
ages and the prevalence of contributing factors such
as obesity, sedentary lifestyle and smoking rise, this
ﬁgure is projected to increase by 60% to 1.56 billion
by the year 2025 (1,2). The risk of hypertension
increases with age and is associated with gender and
ethnicity. The morbidity and mortality associated
with uncontrolled hypertension result in a substantial
economic burden as a result of drug costs, hospitali-
sations, surgery and other healthcare resources. This
cost is compounded by the humanistic burden and
effect on quality of life associated with lifestyle modi-
fying adverse events. Despite global awareness of
hypertension, its consequences and the availability of
effective therapeutics, an estimated 32% of hyperten-
sive patients remain untreated (3). The global prolif-
eration of cost effective, tolerable long-term therapy
is paramount for reducing this growing catastrophe.
Renin-angiotensin-aldosterone-system
and the role of ARBs
The renin-angiotensin-aldosterone-system (RAAS)
plays an integral role in the pathophysiology of
hypertension, functioning as a primary regulator in
the control of ﬂuid volume, electrolyte balance and
blood volume. In conjunction, angiotensin II causes
potent vasoconstriction, aldosterone secretion and
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Objective: To compare the efﬁcacy of valsartan in systolic (SBP) and diastolic
blood pressure (DBP) reduction with other angiotensin II receptor blockers (ARBs)
in essential hypertension. Methods: Systematic literature search of databases
between October 1997 and May 2008. Meta-analysis of short-term, double-blind,
parallel group, randomised controlled trials (RCTs) for treatment of adult hyperten-
sion (DBP: 90–115 mmHg). Random-effects meta-regression adjusting for baseline
blood pressure (BP) was used to analyse the data. Mean change in SBP and DBP
was estimated for each individual drug and dose combination. Results: In all, 31
RCTs (n = 13,110 patients) were included in the analysis. Six studies include trial
arms with candesartan, six irbesartan, 13 losartan, two olmesartan, ﬁve telmisar-
tan and 12 valsartan. The weighted average reduction in mean SBP and DBP for
valsartan 160 mg was )15.32 mmHg (95% CI: )17.09, )13.63) and
)11.3 mmHg (95% CI: )12.15, )10.52) and for 320 mg was )15.85 mmHg
(95% CI: )17.60, )14.12) and )11.97 mmHg (95% CI: )12.81, )11.16); these
are statistically signiﬁcantly greater reductions compared with losartan 100 mg,
which was )12.01 mmHg (95% CI: )13.78, )10.25) and )9.37 mmHg (95% CI:
)10.18, )8.54) for SBP and DBP respectively. There is evidence that valsartan
160 mg reduces SBP and DBP more than irbesartan 150 mg and reduced DBP
more than candesartan 16 mg. No other statistically signiﬁcant difference in efﬁ-
cacy is demonstrated. Conclusion: Valsartan administered at 160 or 320 mg is
more effective at lowering BP than losartan 100 mg and shows comparable efﬁ-
cacy to other ARBs in patients with essential hypertension.
Review Criteria
Data was gathered from prospective double-blind
randomised controlled trials, with at least one ARBs
monotherapy arm with no or forced titration.
Studies had to report change in ofﬁce systolic or
diastolic blood pressure from baseline to follow-up
six to 12 weeks later. A random-effect meta-
regression model was used to estimate the overall
mean change in blood pressure from baseline to
follow-up.
Message for the Clinic
Previous meta-analyses have demonstrated that
ARBs have comparable efﬁcacy. However, none
have included valsartan at 160 and 320 mg. This
paper shows that valsartan at doses of 160 mg or
320 mg is more effective at lowering blood
pressure than losartan 100 mg. For other ARBs at
comparable doses, valsartan achieves comparable
antihypertensive efﬁcacy. Valsartan has a strong
dose–response relationship when increasing from
80 mg to 160 mg or 320 mg.
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766 doi: 10.1111/j.1742-1241.2009.02028.xsympathetic activation, all of which contribute to the
development of hypertension. Angiotensin II receptor
blockers (ARBs) modulate the RAAS system by
blocking the activation of angiotensin II AT1 recep-
tors resulting in, among other effects, vasodilatation,
reduced secretion of vasopressin and reduced pro-
duction and secretion of aldosterone.
There are currently six ARBs used as ﬁrst line
treatment in hypertension: valsartan, candesartan,
irbesartan, losartan, olmesartan and telmisartan. As
the ﬁrst ARBs were introduced in the mid-1990s,
numerous clinical trials have been conducted to eval-
uate their efﬁcacy and tolerability. Concerning valsar-
tan, more than 34,000 patients with hypertension
and its complications have been included in exten-
sive clinical trials such as the Val-HeFT (4), VAL-
IANT (5) and VALUE (6) trials.
Valsartan is a non-peptide, orally active and spe-
ciﬁc angiotensin II antagonist, which demonstrates
high afﬁnity to the AT1 receptor subtype. Although
widely used in the control of hypertension, its use at
higher dose is less widespread. In 2001, valsartan was
approved at starting doses of 160 mg and since then,
there has been continuing evidence supporting its
efﬁcacy in reducing blood pressure (BP) and protect-
ing against clinical events. Studies demonstrate that
the placebo-like tolerability and once daily dosing
schedule of valsartan result in improved patient com-
pliance and treatment persistence, resulting in
increased drug efﬁcacy (7,8). Furthermore, this toler-
ability has been found to be stable over a wide dos-
ing range (9). These advantages, in addition to the
comparative cost-effectiveness of valsartan, mean that
it remains a favourable option for long-term control
of adult hypertension (10).
Dose–response effect: the need for further
analysis
Integrated analysis of valsartan has demonstrated clear
dose-dependent efﬁcacy and ability to achieve BP
goals at doses of 160–320 mg (11); however, there is a
notable absence of head-to-head trials comparing val-
sartan dose 320 mg with other ARBs. The only study
to date is a recent publication by Giles et al. (12)
comparing the efﬁcacy of valsartan, olmesartan me-
doxomil and losartan potassium in a 12-week, forced
titration randomised control trial. Results of this
study demonstrate a dose effect throughout: At treat-
ment week 4, reduction in seated DBP (SeDBP) is
)9.2 mmHg for valsartan 80 mg. At week 8, this
reduction in SeDBP increases to )11.6 mmHg for val-
sartan 160 mg. At week 12, there is a further increase
to )12.4 mmHg for valsartan 320 mg (p < 0.05 vs.
placebo). These results conﬁrm that use of valsartan
at 160 and 320 mg improve BP control.
Results encourage further comparisons at doses of
320 mg. Lack of other head-to-head trials motivates
the need for indirect comparison. In the absence of
said trials, meta-analysis is useful for comparing
ARBs at a range of dosing options. No meta-analysis
to date has compared high-dose (320 mg) valsartan
with other ARBs. Hence, the purpose of this meta-
analysis is to compare high-dose valsartan with other
ARBs in short-term, monotherapy trials with none
or forced titration.
Methods
Literature search
A computerised systematic literature search was con-
ducted using the following databases: MEDLINE,
EMBASE, EMBASE Alert, Cochrane Database of Sys-
tematic Reviews, Cochrane Central Register of Con-
trolled Trials and Science Citation Index (SciSearch).
Both English and German randomised control trials
were searched for, which were published between
October 1997 and May 2008.
Study selection
The following inclusion criteria were applied: pro-
spective double-blind randomised controlled trials
(RCTs); with at least one ARBs monotherapy arm
with no or forced titration; studies recruiting patients
representative of the general hypertension population
(i.e. adults over 18 years, diagnosed with mild⁄mod-
erate essential hypertension DBP: 90–115 mmHg).
Ofﬁce BP measured by automatic or cuff mercury
sphygmomanometer, with measurements of (i) base-
line and follow-up diastolic BP (DBP)⁄systolic BP
(SBP) or (ii) baseline and change in baseline
DBP⁄SBP. The following exclusion criteria were
applied: patients with secondary hypertension, or CV
(except diabetes, left ventricular hypertrophy and
cardiomegaly); studies not reporting withdrawals;
open-label; cross-over; titration to effect and ambula-
tory BP monitoring measurement trials. Studies with
unacceptable methods of randomised allocation,
double blinding and reporting of withdrawals were
excluded. Table 1 shows drugs and dosages consid-
ered, and which doses are considered comparable
between drugs.
Validity assessment and data abstraction
Two independent reviewers completed all phases of
literature selection, review and data abstraction. Dis-
crepancies were resolved by third party consensus.
Selected studies were quality assessed using a quality
assessment tool in accordance with Cochrane Speciﬁ-
cations (13) (see Appendix S1). Data were abstracted
to a customised data extraction sheet which was
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consistency.
For the meta-analytical models, four parameters
were required for each treatment arm and each of
SBP and DBP: the estimate of the mean change in
BP from baseline to follow-up; the SD of this
change; the estimate of the mean BP at baseline and
the number of patients randomised. For inclusion in
the meta-analysis, follow-up must be between 6 and
12 weeks. Where more than one result is available in
this period, from interim analysis, the latest result
has been used. The analysis is performed by dose. In
the case of forced titration studies, the dose is taken
as the maximum dose the patient was titrated to,
rather than the starting dose.
Quantitative data synthesis
A random-effect meta-regression model was used to
estimate the overall mean change in SBP and DBP
from baseline to follow-up. This model adjusts the
estimate of the overall mean change in BP for the
baseline BP. Figure 1 illustrates the relationship
between baseline BP and change in BP, clearly show-
ing that the reduction in BP is higher in trials with
patients with higher BP at baseline. The model esti-
mates the treatment effect by drug and dose. Full
details of these models are given in the Appendix.
Missing data imputation
Both the mean change in BP and the SD of this
change need imputing if they are missing. Baseline
BP data are complete as this is a requirement for
study selection. Missing mean change in BP was
imputed as the difference between mean follow-up
and mean baseline BP. When reported, the change
from baseline BP is commonly the complete case
outcome. When missing, outcomes on all rando-
mised patients were reported at baseline and the
complete cases reported at follow-up, so imputing
missing values in this way is assuming non-informa-
tive drop out. Missing SD of the change from base-
line outcome was imputed from the reported SEM
or the conﬁdence intervals. If these were not given,
then it was imputed using an imputation model,
which uses the mathematical relationship between
the SD at baseline, the SD at follow-up and the SD
of the change in BP. Data from all the trial arms
were used for imputing the missing SD, even if they
contained treatments other than ARBs, doses not
included in the analysis or elective titration arms.
Details of this imputation are given in the Appendix.
Results
Trial ﬂow
Figure 2 shows the trial ﬂow of selection stages for
studies considered for inclusion in the meta-analysis.
From a total of 1601 RCT titles for the publication
period, 418 abstracts were reviewed, 251 of which
were excluded. The most commonly excluded studies
failed to meet the patient population inclusion crite-
ria and hypertension thresholds. From full-text
appraisal, further 138 studies were excluded predom-
inantly for study type (open-label, cross-over), study
duration (> 12 weeks), subpopulations (e.g. diabetic,
renal disease and hyperlipidaemia) and measurement
method (ambulatory BP measurement only). Of the
resultant 29 full-text reports, two contained the
results of two respective RCTs, resulting in 31 data
extracted RCTs (n = 13,110), which were included
for meta-analysis.
Table 1 Doses per day of ARB therapy included in the
meta-analysis
Treatment
(mg⁄day)
Low
dose
Medium
dose
High
dose
Candesartan 8 16 32
Irbesartan – 150 300
Losartan 50 100 –
Olmesartan 10 20 40
Telmisartan – 40 80
Valsartan 80 160 320
Doses are categorised as low, medium or high and are com-
pared with one another within doses. In addition, valsartan
80 mg⁄day vs. irbesartan 150 mg⁄day and valsartan
320 mg⁄day vs. losartan 100 mg⁄day have been compared.
ARB, angiotensin II receptor blocker.
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Figure 1 Observed mean baseline SBP all treatment arms
plotted against the change in SBP. The linear regression
weighted by the inverse of the variance of the change in
SBP is also shown. The area of each circle is inversely
proportional to this variance
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Summary information from the treatment arms of
the RCTs abstracted is given in Table 2.
Quantitative data synthesis
Figure 3 shows the mean change in SBP and DBP by
drug and dose. The results show a dose–response
relationship for all ARBs. In particular, a large
change in response is noted for valsartan when
increasing from 80 to 160 mg and above. Mean
change in SBP for valsartan 80, 160 and 320 mg
increased from )11.52 mmHg (95% CI: )14.39,
)8.70) to )15.32 mmHg (95% CI: )17.09, )13.63)
to a further )15.85 mmHg (95% CI: )17.60,
)14.12). For DBP, this increase was )8.71 mmHg
(95% CI: )9.94, )7.50) to )11.33 mmHg (95% CI:
)12.15, )10.52) to a further )11.97 mmHg (95% CI:
)12.81, )11.16).
Figure 4 shows the indirect comparisons of mean
change from baseline in SBP and DBP by drug and
dose. Greater mean reduction in BP with valsartan
160 and 320 mg was statistically signiﬁcant compared
with losartan 100 mg. Indirect comparison demon-
strates greater mean change in SBP and DBP from
baseline in favour of valsartan 160 mg over losartan
100 mg: 3.31 mmHg (95% CI: 0.86, 5.79) and
1.95 mmHg (95% CI: 0.81, 3.11). No signiﬁcant dif-
ference in BP reduction is seen for valsartan 80 mg
compared with losartan 50 mg: the difference in the
mean change in SBP is 1.59 mmHg (95% CI: )2.44,
5.69) and for DBP is 0.67 mmHg (95% CI: )0.95,
2.35). Irbesartan 150 mg is less effective in reducing
SBP and DBP than valsartan 160 mg, with differ-
ences in the mean change in BP of 3.56 mmHg
(95% CI: 0.77, 6.38) and 2.06 mmHg (95% CI: 0.71,
3.45). Similarly, candesartan 16 mg is less effective in
reducing DBP than valsartan 160 mg, with a differ-
ence in mean change in DBP of 1.85 mmHg (95%
CI: 0.34, 3.40). All other ARBs demonstrate compa-
rable efﬁcacy across dosing ranges.
The estimated value for the meta-regression
parameter b is )0.33 mmHg (95% CI: )0.49, )0.17)
for SBP and )0.14 mmHg (95% CI: )0.30, 0.01) for
DBP. This is interpreted as an average increase of
1 mmHg in the study mean baseline BP leads to an
increase of 0.33 mmHg in SBP and 0.14 mmHg in
DBP reduction.
Discussion
Previous similar meta-analyses have failed to com-
pare the antihypertensive efﬁcacy of valsartan
320 mg with other ARBs. In 2000, Conlin et al. (14)
performed a meta-analysis comparing BP reduction
among ARBs. Main inclusion criteria were prospec-
tive; double-blind RCTs with placebo run in of
*2 of the full texts report results for 2 respective RCTs
Potentially relevant RCT titles 
identified and screened for 
retrieval  (n = 1601)
RCT titles excl (n = 1183) 
publication type     109 
study population   18 
study drug         275 
study design      153 
not hpt               224 
bp not pep         393 
other                  11 
RCT abstracts retrieved for 
more detailed evaluation 
(n = 418)
Potentially appropriate RCT full 
texts to be included in meta-
analysis (n = 167) 
RCT full text with usable  
information data extracted and 
used for meta-analysis (n = 31) 
RCTs full texts included in meta-
analysis (n = 29*)
RCT abstracts excl (n = 251) 
publication type     26 
study population   21 
study drug         41 
study design      92 
not hpt               14 
bp not pep         41 
other                  16 
RCT full text excl (n = 138) 
publication type     12 
study population   17 
study drug         37 
study design      46 
not hpt               2 
bp not pep         10 
study quality                 14 
Study quality includes withdrawals or discrete values not reported, single blind etc 
Other- includes missed dose, placebo run in variation 
bp not pep-change in blood pressure not primary endpoint of study 
not hpt-not hypertension-includes DBP or SBP out of range 
Study design-includes study duration, open label, crossover etc 
Study drug-includes no monotherapy ARB, dose, titration variations etc 
Study population-includes any subpopulations eg women only, diabetics with 
cardiovascular disease, renal failure pts.  
Publication type- includes conference abstracts, reviews, economic evaluations etc 
Figure 2 Trial ﬂow diagram of the literature search resulting in 31 RCTs data extracted
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Drug
Final
dose
Titration
type n
Mean age
(years)
Prop.
male
SBP DBP
References Baseline Change
SD of
change Baseline Change
SD of
change
Candesartan 2 None 59 54 0.49 152 )8.9 14.7 99 )7.1 8.82 Reif et al. (18)*
4 None 63 55 0.7 152 )10.5 13.97 100 )8.4 8.3 Reif et al. (18)*
8 None 82 60 0.57 169 )14 NA 102 )9 NA Andersson and Neldam (19)
60 55 0.57 154 )9.9 14.03 101 )8.7 8.5 Reif et al. (18)
16 None 84 59 0.67 168 )16 NA 103 )10 NA Andersson and Neldam (19)
60 55 0.63 153 )10.7 14.82 100 )7.8 8.89 Reif et al. (18)
Forced 91 54 0.62 150.1 )11.1 NA 100.2 )9.4 NA Zuschke et al. (20)
94 53 0.61 151.9 )12.6 NA 99.8 )10.3 NA Zuschke et al. (20)
32 None 59 55 0.7 152 )12.6 14.5 100 )10.2 8.43 Reif et al. (18)
Forced 332 54.2 0.578 152.6 )13.3 NA 100.1 )10.9 NA Bakris et al. (21)
123 53 0.53 144.9 )15.2 11.88 94.2 )10.2 7.64 Kloner et al. (22)
307 55.5 0.583 153.6 )13.4 NA 100.4 )10.5 NA Vidt et al. (23)
Irbesartan 37.5 None 40 55 0.65 151 )7.5 10.5 100 )7.1 6.7 Kochar et al. (24)*
75 None 55 56.7 0.67 157 )6.6 11.79 101.4 )6.1 7.56 Fogari et al. (25)*
100 None 36 55 0.65 151 )11.1 12.5 100 )9.1 8.9 Kochar et al. (24)*
79 52.8 0.69 149.8 )10.5 11.73 100.7 )9.7 7.55 Pool et al. study 2 (11)*
150 None 53 54.6 0.6 158.9 )11.4 12.38 101 )8.3 7.86 Fogari et al. (25)
57 54.1 0.63 156 )11.6 11.63 101.3 )9.7 7.4 Fogari et al. (25)
134 56.1 0.493 152.8 )12.5 14.01 99.4 )8.88 8.57 Gradman et al. (26)
142 53.1 0.54 155.3 )12.1 13.7 101.1 )9.7 7.75 Kassler-Taub et al. (27)
145 51.9 0.586 156 )11 NA 104 )9.9 NA Oparil et al. (28)
200 None 75 52.8 0.69 149.8 )10.1 11.52 100.7 )9.8 7.36 Pool et al. study 2 (11)*
300 None 140 55.6 0.57 155.4 )16.4 13.37 100.4 )11.7 7.57 Kassler-Taub et al. (27)
43 55 0.65 151 )14.9 9.5 100 )10.2 5.8 Kochar et al. (24)
78 52.8 0.69 149.8 )13 11.75 100.7 )11.6 7.51 Pool et al. study 2 (11)
Losartan 50 None 83 51.8 0.56 164 )14.4 NA 113.6 )10.6 NA Ali et al. (29)
83 59 0.57 168 )15 NA 104 )9 NA Andersson and Neldam (19)
127 53.2 0.65 NA NA NA 102.2 )7.9 9 Ikeda et al. (30)
57 56 0.58 162.4 )10.3 13.59 100.7 )6 7.55 Mallion et al. (31)
93 54.6 0.42 NA NA NA 100.8 )9.1 7.6 Monterroso et al. (32)
146 51.6 0.623 157 )9.5 NA 104 )8.2 NA Oparil et al. (28)
100 None 138 55 0.5 153.3 )11.3 13.39 100.6 )8.7 7.52 Kassler-Taub et al. (27)
Forced 322 54.1 0.584 152 )9.8 NA 99.9 )8.7 NA Bakris et al. (21)
121 57 0.47 162.5 )16 16.4 100.67 )10 9.4 Chung et al. (33)
200 51.3 0.6 155 )13.4 12.63 103.6 )11.5 8.3 Giles et al. (12)
545 55.7 0.575 157.4 )12.8 NA 101.6 )9.7 NA Hedner et al. (34)
304 55.1 0.589 152.2 )10.1 NA 100.2 )9.1 NA Vidt et al. (23)
103 55 0.62 148 )7.3 18.27 95 )6.7 11.16 White et al. (35)
Elective 123 55.1 0.63 NA NA NA 102.2 )8.6 8.3 Ikeda et al. (30)*
Olmesartan 20 None 145 52.4 0.669 157 )11.3 NA 104 )11.5 NA Oparil et al. (28)
40 Forced 199 52.2 0.63 155.4 )13.9 12.6 103.5 )11.7 8.28 Giles et al. (12)
Telmisartan 40 None 71 49.2 0.52 151.1 )17.6 NA 97.2 )11.7 NA Chen et al. (36)
57 58 0.67 161.9 )14.2 13.59 100.8 )8.6 7.55 Mallion et al. (31)
75 51 0.56 153.2 )12.2 14.72 100.7 )10.7 8.66 McGill (37)
72 54.6 0.69 155.2 )11.6 13.58 100.8 )9.3 7.64 Smith et al. (38)
80 None 54 57 0.65 164.2 )15.9 13.23 101.8 )9.7 8.08 Mallion et al. (31)
77 51 0.56 153.2 )15.4 14.92 100.7 )11.5 8.77 McGill (37)
30 51.1 0.6 167.4 )27.7 NA 102.2 )12.4 NA Nalbantgil et al. (39)
72 54.4 0.57 153.7 )11.8 13.58 100 )9.7 7.64 Smith et al. (38)*
120 None 73 53.2 0.66 151.9 )10 12.82 100.2 )8.8 7.69 Smith et al. (38)*
160 None 75 53.4 0.68 154.2 )11.9 12.99 100.5 )8.6 7.79 Smith et al. (38)*
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ate hypertension (DBP: 95–115 mmHg) considered
representative of general hypertensive population;
clinical measurement of BP using cuff⁄mercury
sphygmomanometer; doses recommended in USA,
Japan and Europe and study duration 8–12 weeks.
The following ARBs and doses were included for
analysis: valsartan 80 and 160 mg, losartan 50 and
100 mg, irbesartan 150 and 300 mg and candesartan
8 and 16 mg. This is the most recent meta-analysis
considering valsartan 160 mg, but not 320 mg. From
October 1998, 43 trials (n = 11,281) demonstrated
no clinically meaningful differences in antihyperten-
sive effect. The authors noted that dose titration
(forced and elective) resulted in only a modest
incremental reduction in DBP compared with start-
ing dose, suggesting a relatively ﬂat dose–response
curve.
Table 2 (continued)
Drug
Final
dose
Titration
type n
Mean age
(years)
Prop.
male
SBP DBP
References Baseline Change
SD of
change Baseline Change
SD of
change
Valsartan 40 None 127 55 0.57 153.7 )11.8 11.95 99.2 )10.1 7.55 Philipp et al. study 1 (40)*
80 None 94 54.1 0.49 NA NA NA 100.8 )7 8.5 Monterroso et al. (32)
142 51.7 0.577 155 )8.4 NA 104 )7.9 NA Oparil et al. (28)
124 53.1 0.45 153.2 )12.9 11.8 99.2 )9.7 7.46 Philipp et al. study 1 (40)
58 56 0.66 152.4 )11.2 12.57 99 )10.5 8.15 Pool et al. (41)
160 None 666 55.3 0.52 160.2 )15.7 13.32 101.3 )10.8 8.43 Mallion et al. (42)
1884 55.2 0.553 158.6 )12.97 16 99.81 )10.69 9.59 Parati (43)
128 53 0.54 152 )15.1 11.99 98.9 )11 7.58 Philipp et al. study 1 (40)
207 56.8 0.44 155.6 )20.2 13.96 98.9 )13.3 9.06 Philipp et al. study 2 (40)
166 52.2 0.52 149.6 )14.5 12.63 98.9 )11.7 8.37 Pool et al. (41)
59 55.1 0.49 154.7 )15.5 12.67 99.1 )11 8.22 Pool et al. (41)
Forced 551 54.9 0.567 157 )13.8 NA 101.4 )10.5 NA Hedner et al. (34)
320 None 128 56.8 0.52 154.6 )15.7 11.99 99.3 )13.4 7.58 Philipp et al. study 1 (40)
208 56.7 0.52 157.5 )19.8 13.99 99.1 )13.3 9.09 Philipp et al. study 2 (40)
170 52.5 0.55 149.5 )13.7 12.78 99 )11.3 8.47 Pool et al. (41)
60 56.8 0.52 153.4 )16.5 12.55 98.9 )11.3 8.13 Pool et al. (41)
Forced 197 52.2 0.66 154.3 )14.8 12.17 103.3 )12.4 7.88 Giles et al. (12)
455 52.4 0.62 154.2 )12.8 13.86 100.3 )9.7 8.75 Oparil et al. (44)
1873 54.6 0.565 159.19 )16.1 15.6 99.88 )11.97 9.51 Parati (43)
*Data from all study arms are used in the model for imputing missing SDs, even if the study arm contains a dose for which the treatment effect is not estimated.
Such arms are indicated here. Losartan 100 mg is given in 50 mg bid. Data on ﬁle was also used from Parati (43). SBP, systolic blood pressure; DBP, diastolic
blood pressure; Prop., proportion.
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candesartan 8 mg 
candesartan 16 mg 
candesartan 32 mg 
irbesartan 150 mg 
irbesartan 300 mg 
losartan 50 mg 
losartan 100 mg 
olmesartan 20 mg 
olmesartan 40 mg 
telmisartan 40 mg 
telmisartan 80 mg 
valsartan 80 mg 
valsartan 160 mg 
valsartan 320 mg 
Estimate and 95% CI
−10.04 (−13.89, −6.19)
−12.70 (−15.32,−10.07)
−15.28 (−17.75,−12.80)
−11.75 (−13.91, −9.54)
−15.98 (−18.89,−13.10)
 −9.93 (−12.69, −7.14)
−12.01 (−13.78,−10.25)
−10.88 (−15.63, −6.05)
−13.98 (−18.53, −9.44)
−13.98 (−16.64,−11.23)
−16.50 (−19.26,−13.76)
−11.52 (−14.39, −8.70)
−15.32 (−17.09,−13.63)
−15.85 (−17.60,−14.12)
n
142
329
821
531
261
369
1733
145
199
275
233
324
3661
3091
−13 −11 −9 −8 −7
Change in DBP (mmHg)
●
●
●
●
●
●
●
●
●
●
●
●
●
●
Estimate and 95% CI
 −8.76 (−10.67, −6.83)
 −9.48 (−10.76, −8.17)
−10.79 (−11.96, −9.64)
 −9.27 (−10.34, −8.18)
−11.31 (−12.67, −9.96)
 −8.05 ( −9.16, −6.89)
 −9.37 (−10.18, −8.54)
−11.03 (−13.36, −8.67)
−11.33 (−13.50, −9.11)
−10.21 (−11.53, −8.90)
−10.79 (−12.11, −9.45)
 −8.71 ( −9.94, −7.50)
−11.33 (−12.15,−10.52)
−11.97 (−12.81,−11.16)
n
142
329
821
531
261
589
1733
145
199
275
233
418
3661
3091
Figure 3 Plot of mean change from baseline SBP and DBP by drug and dose. The number of individuals randomised (n) is shown, along with the
estimates and 95% CI of the mean change in BP
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meta-analysis comparing the efﬁcacy across different
antihypertensive drug classes (b-blockers, diuretics,
calcium channel antagonists, angiotensin-converting
enzyme and ARBs). Included studies were in adults
over 18 years with slight-to-moderate hypertension
(SBP: 140–179 mmHg and⁄or DBP: 90–109 mmHg).
RCTs were quality graded according to Jadad speciﬁ-
cations. Drug combinations were not included in
analysis. The ARBs considered were candesartan cil-
exetil 8 and 16 mg, irbesartan 150 and 300 mg,
losartan 50 and 100 mg and valsartan 80 mg used in
monotherapy, at ﬁxed dose or dose increase. Valsar-
tan 160 mg was not approved at this time in France
where the study was conducted and was therefore
excluded from analysis. Between publication period
1973 to 2004, 72 trials were analysed (n = 9094).
Results showed all four ARBs to have comparable
efﬁcacy, although this was not formally tested in the
analysis. Again, comparison between ﬁxed dose and
dose increase regimes did not show greater efﬁcacy
for dose increase.
The same authors updated and expanded the anal-
ysis in 2007 to include more drugs in each class and
added the class renin inhibitors (16). Again, valsartan
160 and 320 mg were not evaluated. Similar inclusion
criteria were applied across studies. The following
ARBs were compared: candesartan 8 and 16 mg, irbe-
sartan 150 and 300 mg, losartan 50 and 100 mg,
olmesartan 20 and 40 mg, telmisartan 40 and 80 mg
and valsartan 80 mg, with comparable results.
Methodologically, the Baguet et al. (15) and Con-
lin et al. (14) meta-analyses use similar approaches,
where the overall change in BP is found from the
weighted average of the estimates from the studies.
However, the weights are the sample sizes and this
has an implied assumption of homogeneous variance
of the underlying population, this is a ﬁxed-effect
meta-analysis. We use the inverse of the variances of
the treatment estimates, which is a more common
meta-analysis modelling approach and use random-
effects meta-analysis. We achieve this by imputing
missing variances. Like the meta-analyses of Baguet
et al. and Conlin et al., our analysis synthesises
within study arm, but not randomised comparisons
within study. This was done because not all studies
use a common comparator and we did not want to
restrict our analysis to only studies where this
occurred. Relative changes between study arms are
generally more homogeneous across studies than
absolute measures from separate study arms. How-
ever, in our case, study patient populations and
study designs are similar and heterogeneity across
trial arms in the change from baseline BP is small.
The studies used in the analysis are all RCTs.
However, the study-level characteristics across studies
have not been randomised, so meta-analysis is obser-
vational in nature. Meta-regression ﬁnds a relation-
ship between the mean change in BP and study-level
characteristics (in this case the baseline BP). BP
reduction is generally larger in patients with a higher
baseline BP. The relationship of baseline BP to
change in BP at the study level may not be the same
as this relationship for individual patients within tri-
als (17). In practice, other studies have shown that
baseline BP is a strong predictor of efﬁcacy. This is a
generic issue with meta-regression at a study level
and individual data are needed to quantify relation-
ships at an individual patient level.
Treatments were compared across doses as deﬁned
in Table 1. At present, a high dose of losartan corre-
sponding to valsartan 320 mg is not available. How-
ever, in the analysis, the highest two dose of
valsartan (160 and 320 mg) are compared with the
highest available dose of losartan (100 mg). Giles et
al. (12) forced titrated losartan and showed an
increase in BP reduction from 100 mg administered
once daily at 8 weeks and 50 mg twice daily at
12 weeks. We took the losartan 50 mg twice daily
dose to be the 100 mg daily dose in our analysis,
−4 −2 0 2 4 6 8 10
Difference in change in SBP (mmHg)
●
●
●
●
●
●
●
●
●
●
●
●
●
Drug and dose
candesartan 8 mg − valsartan 80 mg 
irbesartan 150 mg − valsartan 80 mg 
losartan 50 mg − valsartan 80 mg 
candesartan 16 mg − valsartan 160 mg 
irbesartan 150 mg − valsartan 160 mg 
losartan 100 mg − valsartan 160 mg 
olmesartan 20 mg − valsartan 160 mg 
telmisartan 40 mg − valsartan 160 mg 
candesartan 32 mg − valsartan 320 mg 
irbesartan 300 mg − valsartan 320 mg 
losartan 100 mg − valsartan 320 mg 
olmesartan 40 mg − valsartan 320 mg 
telmisartan 80 mg − valsartan 320 mg 
Estimate and 95% CI
  1.48 ( −3.40,  6.36)
 −0.23 ( −3.85,  3.39)
  1.59 ( −2.44,  5.69)
  2.62 ( −0.49,  5.79)
  3.56 (  0.77,  6.38)
  3.31 (  0.86,  5.79)
  4.43 ( −0.61,  9.52)
  1.34 ( −1.83,  4.59)
  0.57 ( −2.43,  3.56)
 −0.13 ( −3.50,  3.20)
  3.84 (  1.34,  6.31)
  1.87 ( −3.00,  6.79)
 −0.66 ( −3.94,  2.64)
−2 −1 0 1 2 3 4
Difference in change in DBP (mmHg)
●
●
●
●
●
●
●
●
●
●
●
●
●
Estimate and 95% CI
 −0.04 ( −2.32,  2.22)
 −0.56 ( −2.19,  1.07)
  0.67 ( −0.95,  2.35)
  1.85 (  0.34,  3.40)
  2.06 (  0.71,  3.45)
  1.95 (  0.81,  3.11)
  0.30 ( −2.20,  2.86)
  1.12 ( −0.41,  2.65)
  1.18 ( −0.20,  2.59)
  0.66 ( −0.90,  2.26)
  2.60 (  1.45,  3.76)
  0.64 ( −1.68,  3.00)
  1.19 ( −0.38,  2.76)
Figure 4 Plot of indirect comparisons of mean change from baseline, and 95% CI, of SBP and DBP by drug and dose. Positive numbers indicate
that valsartan is superior to the comparator, negative numbers that valsartan is inferior
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of the effect of losartan 100 mg in the meta-analysis.
The current study is the ﬁrst to evaluate indirect
comparisons of ARBs considering high-dose valsartan
and the results demonstrate a dose–response for all
ARBs, with a particularly strong response in valsartan.
Generalisation of the results is limited by the
inclusion and exclusion criteria applied. The analysis
is further limited by scarcity of studies available for
valsartan at high doses. Results are conﬁned to
monotherapy, whereas many patients in clinical prac-
tice receive combination therapy.
Conclusion
This meta-analysis demonstrates that valsartan at
doses of 160 and 320 mg is more effective in reducing
BP than losartan at the 100 mg dose. At comparable
doses, valsartan achieves comparable antihyperten-
sive efﬁcacy to the other ARBs. Findings conﬁrm that
valsartan has a strong dose–response relationship
when increasing from 80 to 160 mg and 320 mg
and that further head-to-head trial are warranted.
The clinical application of these results should take
into consideration the limitations discussed in this
analysis.
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Appendix
Missing data model (SD of the change
from baseline BP)
Missing variance of the change from baseline out-
come when it is missing is estimated using an impu-
tation model and assuming data is missing at
random. The log of the summary statistics (i) SD of
BP at baseline S1, (ii) SD of BP at follow-up S2 and
(iii) SD of the change in BP between baseline and
follow-up Sd are assumed to be sampled from a tri-
variate normal distribution.
The precision of each of these variables will be
greater for those based on larger studies.
The expected value and variance of the maximum
likelihood estimate of a variance are r2 and
2r4=ðn   1Þ respectively, where r2 is the true
variance. Using a delta method approximation, the
variance of the estimate of the log SD is appro-
ximately 1=2ðn   1Þ: In our imputation model, we
weight the variance of the observed SDs by 1⁄n.
Furthermore, we exploit knowledge about the
relationship between the SDs. If q12 is the correlation
between baseline and follow-up BP measures, which
we assume is the same in each arm, i, then
s2
di ¼ s2
1i þ s2
2i   2q12s1is2i ð1Þ
The imputation model for the baseline and follow-
up SDs is
logs1i
logs2i

  BVN ls1
ls2

;
1
ni
r2
s1 qrrs1rs2
qrrs1rs2 r2
s2
 
ð2Þ
and for the change from baseline is
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1
2
log s2
1i þ s2
2i   2q12s1is2i

;
r2
sd
ni

ð3Þ
Meta-analysis model
i indexes the treatment arm across all studies, k(i)
indexes the treatment and dose used. For example,
k(i) takes the value one for candesartan 8 mg. di is
the change in BP from baseline to follow-up; sdi is
the SD of the change in BP between baseline and fol-
low-up; ni is the number of patients at baseline; m1i
is the mean baseline BP, re-centred about the mean.
We use a random-effects meta-regression model for
the change in BP. Although the patients in each
study are randomised, differences between the char-
acteristics of the patients used in the different studies
are not randomised and these may inﬂuence the
treatment effect. Meta-regression can adjust for this.
We can explore how difference in baseline blood
pressure inﬂuences the treatment.
di   Nðci;s2
di=niÞ
ci ¼ di þ bm1i
di   NðlkðiÞ;r2Þ
ð4Þ
where di is the treatment random effect (mean
difference in BP from baseline to follow-up) for
treatment arm i. b is the effect of mean baseline
BP on the change in BP. We assume this is the
same effect across all treatment types. lkðiÞ is the
overall treatment effect of each type of treatment.
r2 is the between study heterogeneity. We assume
this heterogeneity is the same for all types of
treatment.
Model ﬁtting is performed in WinBUGS to
facilitate imputing the missing values and carrying
this uncertainty through into the meta-analysis
models in one step. Each model used three chains,
was burnt in for 5000 iterations per chain, then
run further to sample 20,000 values. All models
mixed well around their stationary distributions.
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